Q1 EPS Forecast for Corcept Therapeutics Lowered by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – HC Wainwright cut their Q1 2025 earnings estimates for Corcept Therapeutics in a research report issued on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.16 per share for the quarter, down from their prior forecast of $0.55. HC Wainwright has a “Buy” rating and a $115.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.57 EPS, FY2025 earnings at $1.93 EPS, FY2026 earnings at $3.80 EPS, FY2027 earnings at $6.26 EPS and FY2028 earnings at $7.34 EPS.

Other equities research analysts have also recently issued research reports about the company. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Finally, Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $99.75.

Corcept Therapeutics Stock Performance

CORT opened at $55.99 on Monday. The stock has a 50-day moving average of $60.12 and a 200-day moving average of $51.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $75.00. The company has a market cap of $5.91 billion, a PE ratio of 44.44 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $59.46, for a total value of $130,812.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of Corcept Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.91, for a total value of $178,100.84. Following the sale, the chief executive officer now directly owns 3,019,411 shares in the company, valued at approximately $183,912,324.01. This trade represents a 0.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,827 shares of company stock worth $2,688,486. Insiders own 20.50% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. M&G PLC acquired a new stake in Corcept Therapeutics during the third quarter worth $11,173,000. Synergy Asset Management LLC boosted its position in shares of Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after acquiring an additional 262,503 shares in the last quarter. Van ECK Associates Corp acquired a new stake in shares of Corcept Therapeutics during the 4th quarter valued at about $4,483,000. Empowered Funds LLC acquired a new position in Corcept Therapeutics in the third quarter worth about $1,784,000. Finally, Victory Capital Management Inc. raised its position in Corcept Therapeutics by 49.2% in the third quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after purchasing an additional 13,787 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.